• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有低级别异型增生的巴雷特食管:在 Barrett 食管转诊单位中升级率较高,提示进展率可能被高估。

Barrett's esophagus with low-grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated.

机构信息

Department of Gastroenterology, St Vincent's Hospital Melbourne, Victoria, Australia; The Faculty of Medicine, University of Melbourne, Victoria, Australia.

Department of Gastroenterology, St Vincent's Hospital Melbourne, Victoria, Australia.

出版信息

Gastrointest Endosc. 2021 Nov;94(5):902-908. doi: 10.1016/j.gie.2021.05.021. Epub 2021 May 24.

DOI:10.1016/j.gie.2021.05.021
PMID:34033852
Abstract

BACKGROUND AND AIMS

The reported progression rate from low-grade dysplasia (LGD) in Barrett's esophagus (BE) to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) ranges from .4% to 13.4% per year. We hypothesize that some reported progression rates may be overestimated because of prevalent HGD or EAC that was not identified during endoscopic assessments performed in the community. Our aim is to determine the proportion of prevalent HGD or EAC detected by BE referral units (BERUs) in patients referred from the community with a recent diagnosis of LGD.

METHODS

All patients referred from the community to 6 BERUs with a diagnosis of BE with LGD were identified. Patients with an assessment endoscopy performed at BERUs more than 6 months from their referral endoscopy in the community were excluded. Visible lesions and histology outcomes were compared between the community referral endoscopy and the assessment endoscopy performed at BERUs.

RESULTS

The median time between BERU assessment and referral endoscopy was 79 days (interquartile range, 54-114). Of the 75 patients referred from the community with LGD, BERU assessment identified HGD or EAC in 20 patients (27%). BERU assessment identified more visible lesions than referral endoscopy performed in the community (39 [52%] vs 9 [12%], respectively; P = .029).

CONCLUSIONS

BERU assessment endoscopy identified more visible lesions than community referral endoscopy and identified HGD or EAC in 27% of patients referred from the community with a recent diagnosis of LGD. Reported progression rates from LGD to HGD or EAC may be overestimated.

摘要

背景与目的

从 Barrett 食管(BE)的低级别异型增生(LGD)进展为高级别异型增生(HGD)或食管腺癌(EAC)的报告进展率为每年 0.4%至 13.4%。我们假设,由于在社区进行的内镜评估中未发现普遍存在的 HGD 或 EAC,因此一些报告的进展率可能被高估。我们的目的是确定在社区转介的 LGD 患者中,由 BE 转介单位(BERU)发现的普遍存在的 HGD 或 EAC 的比例。

方法

确定所有从社区转介至 6 个 BERU 的 BE 伴 LGD 患者。排除在 BERU 进行评估性内镜检查的时间超过社区转介内镜检查后 6 个月的患者。比较社区转介内镜检查和 BERU 进行的评估性内镜检查中的可见病变和组织学结果。

结果

BERU 评估与转介内镜检查之间的中位时间为 79 天(四分位距,54-114)。在 75 例从社区转介的 LGD 患者中,BERU 评估发现 20 例(27%)存在 HGD 或 EAC。BERU 评估发现的可见病变多于社区转介内镜检查(分别为 39 例[52%]和 9 例[12%];P=0.029)。

结论

BERU 评估性内镜检查发现的可见病变多于社区转介内镜检查,并且在最近诊断为 LGD 的社区转介患者中,27%发现 HGD 或 EAC。从 LGD 进展为 HGD 或 EAC 的报告进展率可能被高估。

相似文献

1
Barrett's esophagus with low-grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated.伴有低级别异型增生的巴雷特食管:在 Barrett 食管转诊单位中升级率较高,提示进展率可能被高估。
Gastrointest Endosc. 2021 Nov;94(5):902-908. doi: 10.1016/j.gie.2021.05.021. Epub 2021 May 24.
2
Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.巴雷特食管不典型增生不能确定时的恶性进展风险
Dis Esophagus. 2017 Mar 1;30(3):1-5. doi: 10.1093/dote/dow025.
3
Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.巴雷特食管伴低级别上皮内瘤变或异型增生不明确患者的风险分层。
Clin Gastroenterol Hepatol. 2015 Mar;13(3):459-465.e1. doi: 10.1016/j.cgh.2014.07.049. Epub 2014 Aug 4.
4
A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.一种组织系统病理学检测可发现与巴雷特食管中普遍存在的高级别发育异常和食管癌相关的异常情况。
Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):240-248. doi: 10.1158/1055-9965.EPI-16-0640. Epub 2016 Oct 11.
5
Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer.巴雷特食管伴持续性低级别上皮内瘤变患者高级别上皮内瘤变和癌症风险增加。
Clin Gastroenterol Hepatol. 2016 Jul;14(7):956-962.e1. doi: 10.1016/j.cgh.2015.12.027. Epub 2015 Dec 31.
6
Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.由两名或更多病理学家诊断的巴雷特食管患者从低度发育异常进展为恶性肿瘤。
World J Gastroenterol. 2016 Oct 21;22(39):8831-8843. doi: 10.3748/wjg.v22.i39.8831.
7
Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.过去 20 年中,巴雷特食管在内窥镜下高级别异型增生和腺癌的检出率不断增加:来自美国多中心联盟的数据。
Gastrointest Endosc. 2019 Feb;89(2):257-263.e3. doi: 10.1016/j.gie.2018.09.041. Epub 2018 Oct 17.
8
Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.患有巴雷特食管且证实存在持续低度异型增生的患者发生肿瘤进展的风险增加。
Gastroenterology. 2017 Apr;152(5):993-1001.e1. doi: 10.1053/j.gastro.2016.12.008. Epub 2016 Dec 22.
9
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.巴雷特食管患者低级别上皮内瘤变进展的危险因素。
Gastroenterology. 2011 Oct;141(4):1179-86, 1186.e1. doi: 10.1053/j.gastro.2011.06.055. Epub 2011 Jun 30.
10
Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.巴雷特食管低级别异型增生的诊断和管理:美国胃肠病学会临床实践更新委员会的专家综述。
Gastroenterology. 2016 Nov;151(5):822-835. doi: 10.1053/j.gastro.2016.09.040. Epub 2016 Oct 1.

引用本文的文献

1
Texture and Colour Enhancement Imaging versus White Light Endoscopy for Detection of Dysplasia within Barrett's Oesophagus: A Pilot Study.纹理与颜色增强成像对比白光内镜检查用于检测巴雷特食管内发育异常的初步研究
Digestion. 2025 Jun 16:1-9. doi: 10.1159/000546637.
2
AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.AGA 临床实践指南: Barrett 食管及相关肿瘤的内镜消除治疗。
Gastroenterology. 2024 Jun;166(6):1020-1055. doi: 10.1053/j.gastro.2024.03.019.
3
Endoscopic features of low-grade dysplastic Barrett's.
低度异型增生性巴雷特食管的内镜特征
Endosc Int Open. 2023 Aug 7;11(8):E736-E742. doi: 10.1055/a-2102-7726. eCollection 2023 Aug.
4
High Proportions of Newly Detected Visible Lesions and Pathology Grade Change Among Patients with Barrett's Esophagus Referred to Expert Centers.大量新检出的可见病变和病理分级变化患者中被转诊至专家中心的 Barrett 食管。
Dig Dis Sci. 2023 Sep;68(9):3584-3595. doi: 10.1007/s10620-023-07968-4. Epub 2023 Jul 5.
5
Diagnostic Accuracy of Artificial Intelligence (AI) to Detect Early Neoplasia in Barrett's Esophagus: A Non-comparative Systematic Review and Meta-Analysis.人工智能(AI)检测巴雷特食管早期肿瘤的诊断准确性:一项非比较性系统评价和荟萃分析
Front Med (Lausanne). 2022 Jun 22;9:890720. doi: 10.3389/fmed.2022.890720. eCollection 2022.
6
Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitals.社区医院诊断的巴雷特食管伴固有性低级别上皮内瘤变的专家中心内镜评估的影响。
Endoscopy. 2022 Oct;54(10):936-944. doi: 10.1055/a-1754-7309. Epub 2022 Jan 28.